Martin Evans
Direttore/Membro del Consiglio presso ROQUEFORT THERAPEUTICS PLC
Posizioni attive di Martin Evans
Società | Posizione | Inizio | Fine |
---|---|---|---|
ROQUEFORT THERAPEUTICS PLC | Direttore/Membro del Consiglio | 16/09/2022 | - |
Direttore Tecnico/Scientifico/R&S | 16/09/2022 | 23/05/2024 | |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Direttore Tecnico/Scientifico/R&S | 01/01/2009 | - |
Fondatore | 01/01/2009 | - | |
Presidente | 09/02/2015 | - | |
Direttore/Membro del Consiglio | 26/02/2018 | - | |
Presidente | 01/01/2009 | 09/02/2015 | |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | Direttore/Membro del Consiglio | 01/01/2009 | - |
Direttore Tecnico/Scientifico/R&S | 01/01/2009 | - | |
Fondatore | 01/01/2009 | - | |
Presidente | 01/01/2009 | - | |
Oncogeni Ltd.
Oncogeni Ltd. BiotechnologyHealth Technology Part of Roquefort Therapeutics Plc, Oncogeni Ltd. operates as a British biotechnology company. The company is based in Stratford-upon-Avon, UK. The company was founded in 2019 by Nobel Laureate, Martin John Evans, Trevor Ajan Reginald. Oncogeni was acquired by Roquefort Therapeutics Plc on September 16, 2022 for $4.61 million. | Direttore/Membro del Consiglio | 06/05/2022 | - |
Fondatore | 01/05/2019 | - |
Storia della carriera di Martin Evans
Precedenti posizioni note di Martin Evans
Società | Posizione | Inizio | Fine |
---|---|---|---|
University of Cardiff | Presidente | - | - |
Formazione di Martin Evans
University College London | Doctorate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 7 |
Posizioni
Director/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 3 |
Founder | 3 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ROQUEFORT THERAPEUTICS PLC | Health Technology |
Aziende private | 3 |
---|---|
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Health Technology |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | Health Technology |
Oncogeni Ltd.
Oncogeni Ltd. BiotechnologyHealth Technology Part of Roquefort Therapeutics Plc, Oncogeni Ltd. operates as a British biotechnology company. The company is based in Stratford-upon-Avon, UK. The company was founded in 2019 by Nobel Laureate, Martin John Evans, Trevor Ajan Reginald. Oncogeni was acquired by Roquefort Therapeutics Plc on September 16, 2022 for $4.61 million. | Health Technology |
- Borsa valori
- Insiders
- Martin Evans
- Esperienza